Current Atherosclerosis Reports

, Volume 13, Issue 1, pp 64–72 | Cite as

Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?

  • Keith C. FerdinandEmail author


Statins reduce coronary heart disease (CHD) morbidity and mortality over a wide range of patients. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) in subjects with elevated C-reactive protein, without vascular disease and below average low-density lipoprotein cholesterol (LDL-C) showed a 50% reduction in LDL-C with 20 mg/d of rosuvastatin and a reduction in cardiovascular events (hazard ratio 0.56 [95% CI, 0.46–0.69]; P < 0.00001), and a reduction in total mortality (20%;P < 0.02). Recent commentary has criticized perceived JUPITER design flaws and inappropriate influence. However, the Canadian 2009 guidelines cite JUPITER as class I evidence for statin benefit. Although the Cholesterol Treatment Trialists’ (CTT) Collaborators showed that, regardless of pre-treatment levels, statins can significantly reduce CHD, major vascular events, and overall mortality, a recent primary prevention meta-analysis showed no decrease in all-cause mortality. Preconceived notions on statin benefit or harm do not enhance patient care and clinicians should individualize long-term statin therapy.


Low-density lipoprotein cholesterol (LDL-C) Statins Primary prevention Cardiovascular disease morbidity and mortality 



Keith C. Ferdinand has been a consultant for AstraZeneca and Novartis. He has received grants from Novartis, honoraria from Novartis, AstraZeneca, and Forest, and payment for educational programs from Forest and AstraZeneca.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
  2. 2.
    Grundy SM, Cleeman JI, Merz CN; et al, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227–239.CrossRefPubMedGoogle Scholar
  3. 3.
    British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1–v52.Google Scholar
  4. 4.
    Graham I, Atar D, Borch-Johnsen K; et al, Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28(19):2375–2414.CrossRefPubMedGoogle Scholar
  5. 5.
    The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349–1357.Google Scholar
  6. 6.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344(8934):1383–1389.Google Scholar
  7. 7.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002;360(9326):7–22.Google Scholar
  8. 8.
    •• Ridker PM, Danielson E, Fonseca FA; et al, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21):2195–2207. This is a large placebo-controlled trial demonstrating protection against cardiovascular events and total mortality with intensive 50% LDL-C reduction and average LDL-C levels, but with high hsCRP and baseline LDL-C of only 104 mg/dL. JUPITER appears to extend the evidence for LDL-C lowering with statins to low LDL-C with high hsCRP. CrossRefPubMedGoogle Scholar
  9. 9.
    Shepherd J, Cobbe SM, Ford I; et al, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333(20):1301–1307.CrossRefPubMedGoogle Scholar
  10. 10.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615–1622.CrossRefPubMedGoogle Scholar
  11. 11.
    Shepherd J, Blew GJ, Murphy MB; et al, PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360(9346):1623–1630.CrossRefPubMedGoogle Scholar
  12. 12.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288(23):2998–3007.CrossRefGoogle Scholar
  13. 13.
    Sever PS, Dahlof B, Poulter NR; et al, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361(9364):1149–1158.CrossRefPubMedGoogle Scholar
  14. 14.
    Colhoun HM, Betteridge DJ, Durrington PN; et al, CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet 2004;364(9435):685–696.CrossRefPubMedGoogle Scholar
  15. 15.
    Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29(7):1478–1485.CrossRefPubMedGoogle Scholar
  16. 16.
    Nakamura H, Arakawa K, Itakura H; et al, MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study). Lancet 2006;368(9542):1155–1163.CrossRefPubMedGoogle Scholar
  17. 17.
    Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med 1998; 339:229–23.CrossRefPubMedGoogle Scholar
  18. 18.
    • Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Sherwood Forest Hospitals Foundation Trust and Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009 Feb;26(2):142–8. The Data questions diabetes as marker for increased cardiovascular risk. CrossRefPubMedGoogle Scholar
  19. 19.
    Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010 Jun 26;375(9733):2215–22. Data demonstrates the vascular risk with diabetes and hyperglycemia.CrossRefPubMedGoogle Scholar
  20. 20.
    Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; DOI: 10.1016/S0140-6736(09)61965-6
  21. 21.
    Sever PS, Poulter NR, Dahlof B; et al, ASCOT Investigators. The Anglo-(c Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29(4):499–508.CrossRefPubMedGoogle Scholar
  22. 22.
    Buse JB, Ginsberg HN, Bakris GL; et al, American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115(1):114–126.CrossRefPubMedGoogle Scholar
  23. 23.
    • American Diabetes Association. Clinical practice recommendations—2010. Diabetes Care. 2010;33(suppl 1):S31. The latest guide for clinicians confirms that LDL-C < 100 mg/d (<2.6 mmol/L) is the primary goal of lipid management in adults with diabetes. Google Scholar
  24. 24.
  25. 25.
    Ridker PM and MacFadyen JG. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 105 and 10% to 20% 10-year risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for “intermediate risk.” Circulation: Cardiovascular Quality and Outcomes 2010;3:447–452.CrossRefGoogle Scholar
  26. 26.
    •• Genest J, McPherson R, Frohlich J, et al.: 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 2009;25(10): 567–579. These are the most recent North American guidelines on lipid lowering, and they accept JUPITER as Class I evidence on benefits in the patients studied with elevated hsCRP. PubMedGoogle Scholar
  27. 27.
    Green, Lee A. Cholesterol-lowering therapy for primary prevention: Still much we don’t know. Arch Intern Med 2010;170(12):1007–1008.CrossRefPubMedGoogle Scholar
  28. 28.
    •• Ray K.K., Seshasai S.R.K., Sever P, et al. Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65,229 Participants. Arch Intern Med 2010; 170(12):1024–1031. This is a recent large meta-analysis that challenges the linear, consistent relationship of statins and decreased cardiovascular outcomes, specifically total mortality. CrossRefPubMedGoogle Scholar
  29. 29.
    •• de Lorgeril M, Salen P, Abramson J. et al. Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy: A Critical Reappraisal. Arch Intern Med 2010; 170(12):1032–1036. This is a controversial article highlighting the author’s concerns with perceived designed flaws, conflicts of interest because of industry support and data collection, and the over-interpretation of benefits of JUPITER study. CrossRefPubMedGoogle Scholar
  30. 30.
    Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment. Lancet 2005;366(9493):1267–1278 mortality with no threshold effect. CrossRefPubMedGoogle Scholar
  31. 31.
  32. 32.
    Wright JM, Abramson J. Statins for primary prevention of coronary disease [in reply] Lancet. 2007;369(9567):1079.CrossRefGoogle Scholar
  33. 33.
    Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50(5):409–418.CrossRefPubMedGoogle Scholar
  34. 34.
    Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy. Arch Intern Med 2006;166(21):2307–2313CrossRefPubMedGoogle Scholar
  35. 35.
    Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11(14):1–160Google Scholar
  36. 36.
    Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments. J Am Coll Cardiol 2008;52(22):1769–1781.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ doi:10.1136/bmj.b2376. 2009;338:b2376. This recent, large meta-analysis describes cardiovascular advantages of statins throughout pre-treatment LDL-C range. CrossRefPubMedGoogle Scholar
  38. 38.
    Skerrett PJ, Pasternak RC. ALLHAT-LLT: questions, questions, and more questions (and some answers). Curr Atheroscler Rep 2004 Sep;6(5):375–80.CrossRefPubMedGoogle Scholar
  39. 39.
  40. 40.
    Boutron I, Dutton S, Ravaud, P, and Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303(20):2058–2064.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of CardiologyEmory UniversityAtlantaUSA

Personalised recommendations